Table 2 Phase II/III trials with targeted agents in ovarian cancer (du Bois et al. 2014, 2016; Burger et al. 2011; Oza et al. 2015a; Aghajanian et al. 2015; Poveda et al. 2015; Ledermann et al. 2013; Matulonis et al. 2016; European Medicine Agencies 2016; Marchetti et al. 2015)
First line | Relapse | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Platinum sensitive (PFS > 6 m) | (PFS 0–12 m) | Platinum resistant (<6 m) | |||||||
|  | GOG 218 Bev (11) | ICON7 Bev (12) | AGO Pazopanib (10) | AGO Nintendanib (48) | OCEANS Bev (42) | ICON6 Ced (46) | STUDY 19 Olap (50) | Trinova –1 Trebananib (52) | AURELIA Bev (44) |
DFS/PFS* | 3.8 | 1.7 | 5.6 | 0.7 | 4.0 | 3.1 | 4.0 | 1.8 | 3.3 |
DFS/PFS HR | 0.72 | 0.81 | 0.77 | 0.84 | 0.48 | 0.57 | 0.35 BRCAm 0.18 | 0.66 | 0.48 |
OS* | 0.4 | 0.9 | NA | NR | −1.8 | 2.7 | 2.0 | 1.7 | 3.3 |
OS HR | Â | 0.91 (NS) | 0.99 (NS) (final) | NR | 1.03 (NS) | 0.70 | 0.88 (NS) | 0.86 (NS) | 0.85 (NS) (final) |